JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics ... Foresite Capital, Logos Opportunities Fund ...

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a ...

This year, I predict we will witness an uptick in both early and late-stage asset acquisitions, like Eli Lilly’s acquisition of Scorpion Therapeutics, as companies look to secure innovative ...

J&J revealed a $14.6 billion deal to purchase Intra-Cellular Therapies, maker of bipolar drug Caplyta. Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus ...

paid $2.5 billion for Scorpion Therapeutics. Check out Fierce Biotech’s conference's kickoff coverage here for the full lowdown from Day 1, and go here for Fierce Pharma's Day 2 tracker.